<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7273044\results\search\testTrace\results.xml">
  <result pre="zanamivir are invalid for 2019â€�nCoV and are not recommended for" exact="treatment" post="but protease inhibitors such as lopinavir/ritonavir (LPV/r) inhibit the"/>
  <result pre="and has a stronger antiviral effect than LPV/r. currently, appropriate" exact="treatment" post="for patients with COVIDâ€�19 is an ACE2 inhibitor and"/>
  <result pre="zanamivir are invalid for 2019â€�nCoV and are not recommended for" exact="treatment" post="but protease inhibitors such as lopinavir/ritonavir (LPV/r) inhibit the"/>
  <result pre="and has a stronger antiviral effect than LPV/r. Currently, appropriate" exact="treatment" post="for patients with COVIDâ€�19 is an angiotensinâ€�convertingâ€�enzyme 2 inhibitor"/>
  <result pre="in addition to hydroxychloroquine and corticosteroids. antiviral coronavirus COVIDâ€�19 drug" exact="treatment" post="fig-count: table-count: page-count: word-count: YousefiB, ValizadehS, GhaffariH, VahediA, KarbalaeiM,"/>
  <result pre="SARSâ€�CoVâ€�2 and SARSâ€�CoV RBD to ACE2â€�expressing cells, so inhibiting their" exact="infection" post="to host cells. Therefore, ACE2 also serves as the"/>
  <result pre="improve SARSâ€�CoV RBDâ€�based vaccines for inhibition of SARSâ€�CoVâ€�2 and SARSâ€�CoV" exact="infection" post="(Tai et al.,Â 2020; Wan, Shang, Graham, Baric, &amp;amp;"/>
  <result pre="treat COVIDâ€�19 (FigureÂ 1). Also, potential antiviral therapeutics for experimental" exact="treatment" post="of COVIDâ€�19 shown in TableÂ 1. Figure 1 Molecular"/>
  <result pre="RNAâ€�dependent RNA polymerase Table 1 Potential antiviral therapeutics for experimental" exact="treatment" post="of COVIDâ€�19 Drug Activity Effectiveness The drug's mechanism of"/>
  <result pre="of action in COVIDâ€�19 Kaletra (lopinavir/ritonavir) Used to treat HIV" exact="infection" post="400â€‰mg/100â€‰mg twice daily Protease inhibitor Chloroquine Inhibit quinone reductase"/>
  <result pre="Chloroquine Inhibit quinone reductase 2 that used to treat malaria" exact="infection" post="200â€‰mg, three times per day during 10 days Block"/>
  <result pre="200â€‰mg, three times per day during 10 days Block virus" exact="infection" post="by increasing endosomal pH required for virus/cell fusion, interfering"/>
  <result pre="viruses such as coronaviruses IFNâ€� alpha Used to treat HBV" exact="infection" post="5 million U bid inhalation A broadâ€�spectrum antiviral drug"/>
  <result pre="time, two times/day Umifenovir (Arbidol) Used to treat influenza virus" exact="infection" post="200â€‰mg each time, three times/day Inhibit viral entry into"/>
  <result pre="the immune response Oseltamivir (Tamiflu) Used to treat influenza virus" exact="infection" post="75â€‰mg every 12â€‰hr Neuraminidase inhibitors Ribavirin Used to treat"/>
  <result pre="Teicoplanin A glycopeptide antibiotic that used to treat Gramâ€�positive bacterial" exact="infection" post="To inhibit 50% of viruses (IC50) in vitro was"/>
  <result pre="Teicoplanin A glycopeptide antibiotic commonly used to treat a bacterial" exact="infection" post="is active against SARSâ€�CoV and is on the list"/>
  <result pre="and the hydroxylated form has been suggested as a potential" exact="treatment" post="for patients with SARSâ€�CoVâ€�2 infection. Importantly, the overdose of"/>
  <result pre="et al.,Â 2020). It has also been used in the" exact="treatment" post="of intracellular bacterium Coxiella burnetii both in vitro and"/>
  <result pre="introduced by Gilead Sciences in 2017 to treat Ebola virus" exact="infection" post="and shown to have antiviral activity against Marburg virus,"/>
  <result pre="have been conducted on remdesivir and clinical trials for the" exact="treatment" post="of Ebola virus with remdesivir are ongoing. One study"/>
  <result pre="model (rhesus macaque), the therapeutic effect of remdesivir on MERSâ€�CoV" exact="infection" post="was investigated, with remdesivir being injected 3â€‰hr before virus"/>
  <result pre="as an indicator of improvement in patients, But after starting" exact="treatment" post="with this drug, complications such as digestive adverse effect"/>
  <result pre="unit (ICU). Oseltamivir and zanamivir are firstâ€�line medications for the" exact="treatment" post="and prophylaxis of influenza. Oseltamivir reduces the proliferation of"/>
  <result pre="a clinical trial for Phase 3 for 2019â€�nCoV in the" exact="treatment" post="of COVIDâ€�19 patients with an HIV protease inhibitor (ASC09F)"/>
  <result pre="De Clercq,Â 2020). Oseltamivir has been used orally for the" exact="treatment" post="of 2019â€�nCoV and suspected cases in Chinese hospitals, but"/>
  <result pre="are invalid for nCoVâ€�2019 and are not recommended for the" exact="treatment" post="of patients (Li &amp;amp; De Clercq,Â 2020). 2.3.4 Ribavirin"/>
  <result pre="Days 2â€&quot;5: 600â€‰mg twice daily but its effective dose for" exact="treatment" post="of COVIDâ€�19, and 600â€‰mg tid with 1,600â€‰mg first loading"/>
  <result pre="play an important role in protecting mice from the fatal" exact="infection" post="of wildâ€�type and oseltamivirâ€�resistantâ€�influenza B viruses. Favipiravir has also"/>
  <result pre="But numerous studies show evidence of the ineffectiveness of corticosteroid" exact="treatment" post="on viral pneumonia such as SARSâ€�CoV, MERSâ€�CoV, and H1N1"/>
  <result pre="of high doses of corticosteroids in the early stages of" exact="treatment" post="also has negative effects (Arabi et al.,Â 2018; Jiang"/>
  <result pre="appropriate use of lowâ€�dose corticosteroids may lead to recovery and" exact="treatment" post="for patients with 2019â€�nCoV infection; however, this treatment should"/>
  <result pre="recovery and treatment for patients with 2019â€�nCoV infection; however, this" exact="treatment" post="should be performed following the guidelines recommended for patients"/>
  <result pre="clinical symptoms, such as ARDS or septic shock Systematic corticosteroids" exact="treatment" post="in the first 3â€&quot;5 days could increase oxygen saturation"/>
  <result pre="nucleotide synthesis in lymphocytes and an immunosuppressant in transplantation and" exact="treatment" post="of autoimmune diseases (Diamond, Zachariah, &amp;amp; Harris,Â 2002; Padalko"/>
  <result pre="protein in humans could be useful as a novel biological" exact="treatment" post="to counter or limit the progression of infection caused"/>
  <result pre="novel biological treatment to counter or limit the progression of" exact="infection" post="caused by coronaviruses that use ACE2 as a receptor"/>
  <result pre="this reason, vaccine research should be pursued intensely, until the" exact="infection" post="can be controlled with a protective vaccine to prevent"/>
  <result pre="of high doses of corticosteroids in the early stages of" exact="treatment" post="has negative effects. Generally, corticosteroids should be avoided unless"/>
  <result pre="to resistance to nCoVâ€�2019 and is not recommended for the" exact="treatment" post="of patients. However, the use of hydroxychloroquine as prophylaxis"/>
  <result pre="antiviral activity against coronaviruses. Therefore, the appropriate recommendation for the" exact="treatment" post="of patients with COVIDâ€�19 is a combination of existing"/>
  <result pre="existing drugs. IFNÎ±â€�2b together with ribavirin, when used for the" exact="treatment" post="of MERSâ€�CoV, showed that their effective dose was decreased"/>
  <result pre="as well as its proliferation in infected individuals. Another possible" exact="treatment" post="option could be the use of serums that are"/>
  <result pre="V., Aghayev, F., â€¦ Toovey, S. (2010). Effectiveness of antiviral" exact="treatment" post="in human influenza A (H5N1) infections: Analysis of a"/>
  <result pre="(2020). Soluble angiotensinâ€�converting enzyme 2: A potential approach for coronavirus" exact="infection" post="therapy?Clinical Science, 134(5), 543â€&quot;545.32167153 Behillil, S., May, F., Fourati,"/>
  <result pre="HKU/UCH SARS Study Group (2004). Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: Initial virological and clinical findings. Thorax, 59(3),"/>
  <result pre="M., &amp;amp; Harris, E. (2002). Mycophenolic acid inhibits dengue virus" exact="infection" post="by preventing replication of viral RNA. Virology, 304(2), 211â€&quot;221.12504563"/>
  <result pre="Wang, K. (2019). Efficacy and safety of glucocorticoids in the" exact="treatment" post="of severe communityâ€�acquired pneumonia: A metaâ€�analysis. Medicine, 98(26):e16239.31261585 Khamitov,"/>
  <result pre="disease 2019 in Korea: The application of lopinavir/ritonavir for the" exact="treatment" post="of COVIDâ€�19 pneumonia monitored by quantitative RTâ€�PCR. Journal of"/>
  <result pre="Shah, D., â€¦ Breuer, J. (2020). Favipiravir and zanamivir cleared" exact="infection" post="with influenza B in a severely immunocompromised child. Clinical"/>
  <result pre="(2019). Efficacy and safety of the nucleoside analog GSâ€�441524 for" exact="treatment" post="of cats with naturally occurring feline infectious peritonitis. Journal"/>
  <result pre="B., Wang, W., Zhu, N., â€¦ Tan, W. (2019). Highâ€�throughput" exact="screening" post="and identification of potent broadâ€�spectrum inhibitors of coronaviruses. Journal"/>
  <result pre="T., â€¦ Feldmann, H. (2020). Prophylactic and therapeutic remdesivir (GSâ€�5734)" exact="treatment" post="in the rhesus macaque model of MERSâ€�CoV infection. roceedings"/>
  <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal model. Cell Research, 23(2), 300â€&quot;302.23208422 Yang,"/>
 </snippets>
</snippetsTree>
